Prescription medication · Anti-IL-17 Receptor Monoclonal Antibody
brodalumab
Also sold as Siliq. Siliq treats moderate to severe plaque psoriasis.
Data updated 2026-05-15
- 1,890
- FDA reportsRarely reported
- 2
- InteractionsFew interactions
- Rx
- Availability
What the data shows
brodalumab (Siliq) is a prescription Anti-IL-17 Receptor Monoclonal Antibody, among the least-reported drugs the FDA tracks (1,890 FDA reports), with 2 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
brodalumab (Siliq) is a prescription Anti-IL-17 Receptor Monoclonal Antibody. Siliq treats moderate to severe plaque psoriasis.
Siliq is a medicine used to treat moderate to severe plaque psoriasis. It is for adults who can use systemic therapy or phototherapy and have not responded well to other treatments.
Verify with FDA → · CMS NADAC pricing →
What it does
Siliq treats moderate to severe plaque psoriasis.
Common side effects
Joint pain, Headache, Feeling tired
Key warnings
Siliq may cause suicidal thoughts and behavior.
The sections below are summarized in plain English from brodalumab's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Siliq blocks a protein called interleukin-17 receptor A (IL-17RA). This protein is involved in causing inflammation in psoriasis. By blocking it, Siliq helps reduce the symptoms of psoriasis.
How to Take It
You will receive Siliq as an injection under your skin. The usual dose is 210 mg. You will get an injection at Weeks 0, 1, and 2. After that, you will get an injection every 2 weeks. If you don't see improvement after 12 to 16 weeks, talk to your doctor about stopping treatment.
This is a plain-language summary of brodalumab's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
It is not known if Siliq can harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. It is also not known if Siliq passes into breast milk. Talk to your doctor about the risks and benefits of breastfeeding while using Siliq.
This is a plain-language summary of brodalumab's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
If you miss a dose of Siliq, inject it as soon as you remember. Then, continue with your regular schedule.
This is a plain-language summary of brodalumab's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Store Siliq in the refrigerator at 36°F to 46°F (2°C to 8°C) in its original carton to protect it from light.
Side Effects (from patient reports)
Based on 1,890 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for brodalumab, by number of reports
- Psoriasis
Psoriasis
471 reports
- Joint pain 181
Joint pain
181 reports
- Tiredness 163
Tiredness
163 reports
- Psoriatic arthritis 156
Psoriatic arthritis
156 reports
- Disease coming back 129
Disease coming back
129 reports
- Headache 126
Headache
126 reports
- Treatment stopped temporarily 124
Treatment stopped temporarily
124 reports
- Giving the medicine at the wrong time 115
Giving the medicine at the wrong time
115 reports
- Diarrhea 91
Diarrhea
91 reports
- COVID-19 87
COVID-19
87 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for brodalumab each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where brodalumab sits
brodalumab has more FDA adverse-event reports than 12% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is brodalumab; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,890 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
1,890
Reports Mentioning Death
133
7.0% of reports — not proof of cause
Hospitalization Reports
535
Top Indication
Psoriasis
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | PSORIASIS | 471 |
| 3 | ARTHRALGIA | 181 |
| 4 | FATIGUE | 163 |
| 5 | PSORIATIC ARTHROPATHY | 156 |
| 8 | DISEASE RECURRENCE | 129 |
| 9 | HEADACHE | 126 |
| 10 | THERAPY INTERRUPTED | 124 |
| 12 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 115 |
| 13 | DIARRHOEA | 91 |
| 14 | COVID-19 | 87 |
| 15 | PAIN IN EXTREMITY | 87 |
| 16 | THERAPY CESSATION | 85 |
| 17 | CONDITION AGGRAVATED | 80 |
| 18 | PRURITUS | 77 |
| 19 | PATIENT DISSATISFACTION WITH TREATMENT | 74 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Siliq may cause suicidal thoughts and behavior. Tell your doctor if you have a history of depression or suicidal thoughts. If you have new or worsening suicidal thoughts or depression, get medical help right away. Siliq is only available through a special program because of this risk.
Known Drug Interactions
Therefore, upon initiation or discontinuation of SILIQ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate [see Clinical Pharmacology ( 12.3 )].
Mechanism: Brodalumab can change how your liver enzymes break down other medicines like warfarin. This can cause the amount of warfarin in your body to go up or down.
What to do: Your doctor should monitor your blood clotting tests closely and may need to adjust your dose when you start or stop this medicine.
Therefore, upon initiation or discontinuation of SILIQ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate [see Clinical Pharmacology ( 12.3 )].
Mechanism: Brodalumab may affect the liver enzymes that process cyclosporine, which can lead to changes in the amount of medicine in your blood.
What to do: Your doctor should check your blood levels of cyclosporine and may need to change your dose when you start or stop this treatment.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
What should I do before starting Siliq?
Can Siliq cause allergic reactions?
What if I get an infection while taking Siliq?
Can I get vaccines while using Siliq?
What if I have new or worsening depression while on Siliq?
How long can Siliq be stored at room temperature?
What does Siliq look like?
How is Siliq given?
What if Siliq doesn't work after a few months?
Can Siliq affect other medicines I'm taking?
What are the common side effects of brodalumab?
Does brodalumab interact with other medications?
What drug class is brodalumab?
Is brodalumab safe during pregnancy?
Related Medications in Anti-IL-17 Receptor Monoclonal Antibody
Other drugs grouped near brodalumab - same-class peers and common alternatives.
adapalene
Differin
Compare with brodalumab →
apremilast
Otezla
Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis.
Compare with brodalumab →
azelaic acid
Finacea, Azelex
Azelaic acid gel is a topical medicine that helps treat rosacea.
Compare with brodalumab →
benzoyl peroxide
Benzac, PanOxyl
Benzoyl peroxide is a topical medicine that fights germs on your skin.
Compare with brodalumab →
betamethasone
Diprosone, Luxiq
Betamethasone dipropionate cream is a strong steroid medicine used on the skin.
Compare with brodalumab →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on brodalumab
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for brodalumab
The FDA label for brodalumab (sold under brand names such as Siliq) classifies it as a prescription-only medication in the Anti-IL-17 Receptor Monoclonal Antibody class. Siliq treats moderate to severe plaque psoriasis. Official labeling lists 11 commonly reported side effects, including Joint pain, Headache, Feeling tired.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,890 voluntary reports. The database also lists 2 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: February 11, 2026
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages